...
机译:将常规治疗与免疫疗法结合起来:风险的业务?
UZ Leuven Dept Gynaecol &
Obstet Leuven Canc Inst Leuven Belgium;
Katholieke Univ Leuven Lab Tumour Immunol &
Immunotherapy Dept Oncol ImmunOvar Res Grp Leuven;
Katholieke Univ Leuven Lab Tumour Immunol &
Immunotherapy Dept Oncol ImmunOvar Res Grp Leuven;
Bioceros BV Utrecht Netherlands;
Katholieke Univ Leuven Lab Tumour Immunol &
Immunotherapy Dept Oncol ImmunOvar Res Grp Leuven;
Katholieke Univ Leuven Lab Tumour Immunol &
Immunotherapy Dept Oncol ImmunOvar Res Grp Leuven;
Univ Oxford Early Phase Clin Trials Unit Dept Oncol Oxford England;
UZ Leuven Dept Haematol Leuven Canc Inst Leuven Belgium;
Med Univ Innsbruck Dept Gynaecol &
Obstet Innsbruck Austria;
Copenhagen Univ Hosp Rigshosp Copenhagen Denmark;
UCL UCL Canc Inst London England;
KEM Dept Gynaecol &
Gynaecol Oncol Essen Germany;
UZ Leuven Dept Gynaecol &
Obstet Leuven Canc Inst Leuven Belgium;
Immunotherapy; Tumor immunology; Chemotherapy; Combination; Survival;
机译:将常规治疗与免疫疗法结合起来:风险的业务?
机译:将靶向和常规癌症治疗与免疫疗法结合的前景
机译:将常规化学疗法和基于γδT细胞的免疫疗法相结合,可靶向靶向癌细胞。
机译:联合化学疗法和免疫疗法的鲁棒性最佳计划:关于化学疗法有害影响的考虑
机译:溶瘤病毒和免疫疗法模型结合减轻癌症负担的策略。
机译:非小细胞肺癌常规放疗联合免疫疗法的简要回顾
机译:将常规化学疗法和基于γδT细胞的免疫疗法相结合,以靶向癌症起始细胞。